BDSI logo

BioDelivery Sciences International (BDSI) Stock

Profile

Sector:

Healthcare

Industry:

Drug Manufacturers - Specialty & Generic

Country:

United States

IPO:

25 July 2002

Indexes:

Not included

Website:

http://www.bdsi.com

Description:

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$166.70 M

Annual EPS

$0.82

PE Ratio

-

Annual ROE

57.33%

Annual Debt To Equity

0.31

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

May 10, 2023

Recent annual earnings:

Mar 10, 2021
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

15 Feb '22 Piper Sandler
Neutral
21 Jan '22 HC Wainwright & Co.
Neutral
04 Nov '21 HC Wainwright & Co.
Neutral
05 Aug '21 HC Wainwright & Co.
Buy
11 Mar '21 HC Wainwright & Co.
Buy
18 Dec '19 SunTrust Robinson Humphrey
Buy
20 Mar '19 SunTrust Robinson Humphrey
Buy
23 May '18 H.C. Wainwright
Buy
26 Jan '18 Seaport Global
Buy
17 May '17 Cantor Fitzgerald
Overweight

Screeners with BDSI included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$18.15
BDSI price is currently at an all-time high

Price Analysts Target

$5.60
BDSI price is currently equal to the consensus analysts' forecast

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue 3-Year Change

+6.54%
BDSI annual revenue is up +6.54% over the past 3 years

Annual Revenue Estimate

$201.58 M
BDSI annual revenue is currently -17.30% lower than the consensus analysts' forecast

Annual Net Income 3-Year Change

+230.05%
BDSI annual net profit is up +230.05% over the past 3 years

Annual EPS 3-Year Change

+241.67%
BDSI annual earnings per share is up +241.67% over the past 3 years

Annual Gross Profit

$143.33 M
BDSI annual gross profit is $143.33 million

Annual Operating Profit

$37.12 M
BDSI annual operaing income is $37.12 million

Annual Operating Profit 3-Year Change

+12.57%
BDSI annual operaing income is up +12.57% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

57.33%
BDSI annual return on equity is 57.33%

Annual ROA

30.07%
BDSI annual return on assets is 30.07%

Annual EBIT

$37.12 M
BDSI annual earnings before interest & taxes is $37.12 million

Annual EBITDA

$44.54 M
BDSI annual earnings before interest, taxes, depreciation & amortization is $44.54 million

Annual Interest Coverage Ratio

4.95
BDSI annual interest coverage ratio is 4.95

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Quick Ratio

2.17
BDSI annual quick ratio is 2.17

Annual Current Ratio

2.45
BDSI annual current ratio is 2.45

Annual Total Assets

$324.60 M
BDSI annual total assets is $324.60 million

Annual Current Assets

$202.06 M
BDSI annual total current assets is $202.06 million

Annual Total Liabilities

$136.77 M
BDSI annual total liabilities is $136.77 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+64.27%
BDSI annual cash flow from operations is up +64.27% over the past 3 years

Annual CFI 3-Year Change

-52761.54%
BDSI annual cash flow from investing activities is down -52761.54% over the past 3 years

Annual CFF 3-Year Change

-238.33%
BDSI annual cash flow from financing activities is down -238.33% over the past 3 years

Annual CAPEX

$415.00 K
BDSI annual capital expenditures is $415.00 thousand

Annual CAPEX 3-Year Change

+3092.31%
BDSI annual capital expenditures is up +3092.31% over the past 3 years

Annual FCF

$40.62 M
BDSI annual free cash flow is $40.62 million

Annual FCF 3-Year Change

+62.7%
BDSI annual free cash flow is up +62.7% over the past 3 years

Institutional Ownership

Similar stocks

FAQ

  • What is the primary business of BioDelivery Sciences International?
  • What is the ticker symbol for BioDelivery Sciences International?
  • Does BioDelivery Sciences International pay dividends?
  • What sector is BioDelivery Sciences International in?
  • What industry is BioDelivery Sciences International in?
  • What country is BioDelivery Sciences International based in?
  • When did BioDelivery Sciences International go public?
  • Is BioDelivery Sciences International in the S&P 500?
  • Is BioDelivery Sciences International in the NASDAQ 100?
  • Is BioDelivery Sciences International in the Dow Jones?
  • When was BioDelivery Sciences International's last earnings report?
  • When does BioDelivery Sciences International report earnings?
  • Should I buy BioDelivery Sciences International stock now?

What is the primary business of BioDelivery Sciences International?

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.

What is the ticker symbol for BioDelivery Sciences International?

The ticker symbol for BioDelivery Sciences International is NASDAQ:BDSI

Does BioDelivery Sciences International pay dividends?

No, BioDelivery Sciences International does not pay dividends

What sector is BioDelivery Sciences International in?

BioDelivery Sciences International is in the Healthcare sector

What industry is BioDelivery Sciences International in?

BioDelivery Sciences International is in the Drug Manufacturers - Specialty & Generic industry

What country is BioDelivery Sciences International based in?

BioDelivery Sciences International is headquartered in United States

When did BioDelivery Sciences International go public?

BioDelivery Sciences International's initial public offering (IPO) was on 25 July 2002

Is BioDelivery Sciences International in the S&P 500?

No, BioDelivery Sciences International is not included in the S&P 500 index

Is BioDelivery Sciences International in the NASDAQ 100?

No, BioDelivery Sciences International is not included in the NASDAQ 100 index

Is BioDelivery Sciences International in the Dow Jones?

No, BioDelivery Sciences International is not included in the Dow Jones index

When was BioDelivery Sciences International's last earnings report?

BioDelivery Sciences International's most recent earnings report was on 10 May 2023

When does BioDelivery Sciences International report earnings?

The date for BioDelivery Sciences International's next earnings report has not been announced yet

Should I buy BioDelivery Sciences International stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions